1. Home
  2. STAA vs CAPR Comparison

STAA vs CAPR Comparison

Compare STAA & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo STAAR Surgical Company

STAA

STAAR Surgical Company

HOLD

Current Price

$27.68

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$21.40

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STAA
CAPR
Founded
1982
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
1995
2011

Fundamental Metrics

Financial Performance
Metric
STAA
CAPR
Price
$27.68
$21.40
Analyst Decision
Buy
Strong Buy
Analyst Count
9
8
Target Price
$22.81
$44.63
AVG Volume (30 Days)
634.0K
1.6M
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.10
N/A
Revenue
$239,442,000.00
N/A
Revenue This Year
$30.82
N/A
Revenue Next Year
$8.41
$3.31
P/E Ratio
$279.70
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.59
$4.30
52 Week High
$35.87
$40.37

Technical Indicators

Market Signals
Indicator
STAA
CAPR
Relative Strength Index (RSI) 44.97 30.44
Support Level $23.75 $5.25
Resistance Level $31.17 $30.39
Average True Range (ATR) 1.35 1.58
MACD -0.17 -0.40
Stochastic Oscillator 33.70 2.67

Price Performance

Historical Comparison
STAA
CAPR

About STAA STAAR Surgical Company

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: